Sites
Tags
- A
- ABCG2
- Abemaciclib
- Accelerated approval
- Ace inhibitor
- Acetylcholinesterase inhibitor
- Adenosine deaminase
- Aflibercept
- Alpha-glucosidase inhibitor
- Alvocidib
- American Society of Health-System Pharmacists
- Aminolevulinic acid
- Aminopterin
- Anemia
- Anthracycline
- Anthraquinone
- Antifolate
- Antimetabolite
- Aromatase inhibitor
- Aromatic L-amino acid decarboxylase inhibitor
- Arsenic trioxide
- Asparagine
- AstraZeneca
- Atrasentan
- Atrial fibrillation
- Axicabtagene ciloleucel
- Azacitidine
- Aziridine
- Bexarotene
- Biological half-life
- BioMarin Pharmaceutical
- Bleomycin
- Bloomberg News
- Bortezomib
- BRCA1
- BRCA2
- BRCA mutation
- Breast cancer
- Busulfan
- Camptotheca
- Camptothecin
- Cancer
- Cancer patients
- Capecitabine
- Carbonic anhydrase inhibitor
- Carboplatin
- Carfilzomib
- Carmustine
- CAS Registry Number
- Celecoxib
- Cell Cycle
- ChEMBL
- Chemical formula
- Chemotherapy
- ChemSpider
- Chlorambucil
- Chlormethine
- Cisplatin
- Cladribine
- Clinical trial
- Clofarabine
- Colorectal cancer
- Combination
- Competitive inhibition
- COX-2 inhibitor
- Cyclin-dependent kinase
- Cyclophosphamide
- Cytarabine
- Dacarbazine
- Dactinomycin
- DailyMed
- Decitabine
- Deoxyribonucleotide
- Dihydrofolate reductase inhibitor
- Dipeptidyl peptidase-4 inhibitor
- DNA damage
- DNA repair
- DNA replication
- Docetaxel
- DOI
- Doxorubicin
- DrugBank
- Drug class
- Drug metabolism
- Drug nomenclature
- Eflornithine
- Eisai
- Elesclomol
- Entinostat
- Enzalutamide
- Enzyme
- Enzyme inhibitor
- Epirubicin
- Eribulin
- ESMO
- Etoposide
- European Chemicals Agency
- European Medicines Agency
- Excretion
- Fallopian tube cancer
- Fatigue
- Feces
- Fludarabine
- Fluorouracil
- Food and Drug Administration
- Fotemustine
- Gemcitabine
- Germline mutation
- Geron Corporation
- Gynecologic oncology
- Hair loss
- Halogenation
- Health Canada
- Histone deacetylase inhibitor
- Homologous recombination
- Hydrazine
- Hydrolase
- Hydroxycarbamide
- Hypomethylating agent
- Idelalisib
- Ifosfamide
- Incyte
- Integrase inhibitor
- Intercalation
- International Chemical Identifier
- Irinotecan
- Janus kinase inhibitor
- Jmol
- KEGG
- Lomustine
- Lucanthone
- Lyase
- M
- Matrix metalloproteinase inhibitor
- Medivation
- MedlinePlus
- Melphalan
- Menzie
- Mercaptopurine
- Methotrexate
- Microtubule
- Mitomycins
- Mitotic inhibitor
- Mitoxantrone
- Mitozolomide
- Molar mass
- Monoamine oxidase inhibitor
- Myocardial infarction
- Nausea
- Navitoclax
- Nelarabine
- Neuraminidase inhibitor
- Neuroblastoma
- Neurodegeneration
- Neutropenia
- Neutrophil
- Niraparib
- Nitrogen mustard
- Nitrosourea
- Non-competitive inhibition
- Non-small-cell lung carcinoma
- Olaparib
- Oral administration
- Ovarian cancer
- Oxaliplatin
- Oxidoreductase
- Paclitaxel
- Palbociclib
- Panobinostat
- PARP
- PARP1
- PARP2
- PARP inhibitor
- Pemetrexed
- Pentostatin
- Pfizer
- P-glycoprotein
- Pharmacokinetics
- Pharmacology
- Phases of clinical research
- Phosphodiesterase inhibitor
- Phosphoinositide 3-kinase inhibitor
- Photodynamic therapy
- Photosensitizer
- Plasma protein binding
- Platelet
- Platinum-based antineoplastic
- PMC
- Podophyllum
- Poly ADP ribose polymerase
- Polygalacturonase inhibitor
- Polymerase chain reaction inhibitors
- Porphyrin
- Pregnancy category
- Prescription drug
- Primary peritoneal carcinoma
- Procarbazine
- Prostate cancer
- Prostate cancer research
- Protease inhibitor
- Proteasome inhibitor
- Protein Data Bank
- Protein kinase inhibitor
- PTEN
- Public domain
- PubMed
- Purine analogue
- RAD51
- Radiation therapy
- Receptor antagonist
- Regulation of therapeutic goods
- Retinoid
- Retinoid X receptor
- Reverse-transcriptase inhibitor
- Ribociclib
- Ribonuclease inhibitor
- Route of administration
- Rucaparib
- Sanofi
- Semustine
- Sex steroid
- S phase
- Standard for the Uniform Scheduling of Medicines and Poisons
- Statin
- Streptomyces
- Streptozotocin
- Stroke
- Surface epithelial-stromal tumor
- Talazoparib
- Talimogene laherparepvec
- Taxane
- Tegafur
- Tegafur/gimeracil/oteracil
- Temozolomide
- Teniposide
- Therapy
- Thiopurine
- ThioTEPA
- Thrombocytopenia
- Tioguanine
- Tisagenlecleucel
- Topoisomerase inhibitor
- Topotecan
- Trabectedin
- Transferase
- Tretinoin
- Triple-negative breast cancer
- Trypsin inhibitor
- Type II topoisomerase
- Tyrosine-kinase inhibitor
- Valrubicin
- Veliparib
- Venetoclax
- Verteporfin
- Vinblastine
- Vinca alkaloid
- Vincristine
- Vindesine
- Vinflunine
- Vinorelbine
- Vorinostat
- WHO Model List of Essential Medicines
- Xanthine oxidase inhibitor
- Β-Lactamase inhibitor